Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

IMDX vs XBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XBIO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 3–4 Matrix Metrics)

XBIO Overall Winner 6-Pillar Tally: IMDX 1 – 4 XBIO (1 Tie) Matrix Metrics: IMDX 4 – 3 XBIO

As of Nov 19, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas XBIO carries 52.8/100 (HOLD) at $1.54 (N/M Forward P/E, -81.0% operating margin).

  • Growth vs. Quality Trade-Off: XBIO earns the overall head-to-head edge with a stronger Unified Composite Score (52.8/100 HOLD vs. IMDX 45.5/100 HOLD) and 1.54β · 99% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMDX vs XBIO
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.91β · 76% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $2.51 · SMA50: $3.10
XBIO NASDAQ Head-to-Head Winner
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.54
+0.65% 1D
Market Cap $3.6M
TTM Revenue $3.3M
Forward P/E N/M
Beta / 30D Vol 1.54β · 99% Vol
Unified Composite Score
52.8 / 100 HOLD
Tech 58.0 Fund 53.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.1%), weak momentum, RSI 34
RSI-14: 33.6 · SMA20: $1.83 · SMA50: $2.19

6-Pillar Scorecard Institutional Category Breakdown (IMDX 1 – 4 XBIO)

Columns: Metric · IMDX · XBIO
1. Valuation Multiples XBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.8x 1.1x
2. Growth & Scale IMDX
Revenue Growth (YoY) +115.0% +12.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.0M $3.3M
Market Cap $52.1M $3.6M
3. Profitability & Quality XBIO
Gross Margin 55.6% 100.0%
Operating Margin -1883.2% -81.0%
Net Profit Margin 0.0% -75.9%
Return on Equity (ROE) -23603.1% -47.0%
4. Balance Sheet & Cash Flow XBIO
Cash Generation (TTM) -$31M -$1.8M
Cash Flow Margin N/A -55.8%
Net Cash / Leverage $15M Net Cash $3.23 Book/Sh · -47.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XBIO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 99.4% (12th %ile) N/A (N/A)
Put/Call OI Skew 0.08x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMDX (4) vs XBIO (3)
Institutional Metric IMDX XBIO Criterion Row Edge
Market Capitalization
Scale
$52.1M $3.6M Larger Scale IMDX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+115.0% +12.0% Higher Growth IMDX
Operating Margin (TTM)
Profitability
-1883.2% -81.0% Higher Margin XBIO
Net Profit Margin
Profitability
0.0% -75.9% Higher Margin IMDX
Return on Equity (ROE)
Capital Efficiency
-23603.1% -47.0% Higher ROE XBIO
52-Week Range Position
Momentum
3% ($2–$8) 3% ($1–$5) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
2.91β · 76% Vol 1.54β · 99% Vol Lower Realized Risk IMDX
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 52.8 / 100 (HOLD) Higher Composite XBIO
Trailing 12M Revenue (USD)
Operating Scale
$2.0M $3.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
55.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.8x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($15M Net Cash) -$1.8M ($3.23 Book/Sh · -47.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XBIO +21.27 pp
IMDX: -45.03% · XBIO: -23.76%
3M Horizon XBIO +4.65 pp
IMDX: -61.75% · XBIO: -57.1%
6M Horizon XBIO +24.15 pp
IMDX: -71.77% · XBIO: -47.62%
1Y Horizon XBIO +33.7 pp
IMDX: -73.78% · XBIO: -40.08%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IMDX Revenue XBIO Revenue IMDX Op. Margin XBIO Op. Margin Margin Leader
FY2017 N/A $10M N/A -47.1% XBIO
FY2019 N/A $0M N/A -75511.7% XBIO
FY2020 $0M $0M -2443.3% -3189.8% IMDX
FY2021 $0M $0M -2444.3% -495.1% XBIO
FY2022 $0M $0M -1878.6% -393.6% XBIO
FY2023 $0M $0M -1672.4% -177.8% XBIO
FY2024 $0M $0M -3245.1% -168.2% XBIO
FY2025 $0M $0M -1260.8% -95.2% XBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMDX BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 99.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMDX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $52.1M market capitalization and -1883.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6M market capitalization and -81.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMDX vs XBIO Key Questions & Quantitative Answers

As of Nov 19, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas XBIO carries 52.8/100 (HOLD) at $1.54 (N/M Forward P/E, -81.0% operating margin). Growth vs. Quality Trade-Off: XBIO earns the overall head-to-head edge with a stronger Unified Composite Score (52.8/100 HOLD vs. IMDX 45.5/100 HOLD) and 1.54β · 99% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMDX leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with XBIO at +12.0% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (100.0% gross margin, -81.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), IMDX cumulative revenue shifted N/A while XBIO shifted N/A. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XBIO.

XBIO screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas XBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-55.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus XBIO (-47.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, XBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.54β · 99% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.